PPARγ agonists also inhibit tau phosphorylation, and because plasma p-tau 181 is associated with the metabolic and cognitive deficits associated with AD (Lussier et al., 2021), incorporation of a standardized, sensitive test for p-tau 181 (Karikari et al., 2020) would also be useful. This evidence concerns the gene MAPT and Alzheimer disease.